Middle East crisis live: Israel orders closure of one of last functioning hospitals in northern Gaza
Head of Kamal Adwan hospital says it is ‘next to impossible’ to obey shut down order due to lack of ambulances to evacuate patients
Related Articles
UK refuses 4-yr-old Gazan boy medical treatment
The UK government has refused to allow a four-year-old boy from Gaza to enter the country for medical treatment. Ahmed lost both his legs and…
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.
Circulating Tumor HPV DNA Testing in Patients With a Lateral Neck Mass
This diagnostic study assesses the performance metrics of tumor tissue–modified human papillomavirus (HPV) DNA testing for diagnosing oropharyngeal squamous cell carcinoma in patients with a…
Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Updates on the Phase I trial of rocbrutinib (LP-168), a novel BTKi, for the treatment of CLL
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, presents an update on a Phase I trial of rocrutinib (NCT04775745), a novel fourth-generation covalent and…
Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer
CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.
Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.
Mary Did You Know | Acoustic Guitar | Vlogmas
For the last video for Vlogmas (Day 22), I’m back with the guitar. This song has been a Christmas favourite since high school ;)Today (Day…
Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.